|
イハラ トシコ
Toshiko Ito-Ihara
猪原 登志子 所属 川崎医科大学 医学部 応用医学 先端医療開発学 職種 教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Clinical trial evaluating the efficacy and safety of percutaneous prostate cancer lesion-targeted microwave tissue coagulation for prostate functional preservation: MicroPro2. |
| 掲載誌名 | 正式名：International journal of surgery protocols 略 称：Int J Surg Protoc ISSNコード：24683574/24683574 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 29(3),pp.93-101 |
| 著者・共著者 | Atsuko Fujihara, Takumi Shiraishi, Go Horiguchi, Takashi Ueda, Masatsugu Miyashita, Yuta Inoue, Yayoi Iwami, Akari Naito, Satoshi Teramukai, Toshiko Ito-Ihara, Osamu Ukimura |
| 発行年月 | 2025/09 |
| 概要 | INTRODUCTION:Focal therapy (FT) for localized prostate cancer (PC) aims to achieve cancer control and maintain quality of life. Microwave tissue coagulation (MTC) is a tissue-coagulation thermotherapy that has been used to treat solid tumors such as kidney, liver, and lung tumors. However, the use of this technology in lesion-targeted FT for PC has not been established.METHODS:We will perform a prospective multi-center, single-arm, clinical study to evaluate the efficacy and safety of lesion-targeted focal MTC for localized PC. In eight centers with expert urologists for performing magnetic resonance imaging (MRI)/ultrasound (US) fusion biopsy, patients will be evaluated prospectively after lesion-targeted MTC. The target sample size is 65. This study was registered with the Japan Registry of Clinical Trials and ClinicalTrials.gov. Inclusion criteria were patients who had a single MRI-visible lesion with Prostate Imaging Reporting and Data System (PI-RADS) category 3 or 4 that was proven as Gleason score of 7 or 8 cancer by enrollment biopsy or patients who had a single MRI-visible lesion with PI-RADS category 4 or 5 that was proven as Gleason score of 6 or 7 by enrollment biopsy. The primary endpoint is the disappearance of the targeted cancer lesion at 6 months after microwave coagulation, evaluated by a combined response in prostate-specific antigen, MRI, and prostate biopsy.DISCUSSION:The importance of this clinical trial is to establish a new ablative treatment option for lesion-targeted FT in PC. |
| DOI | 10.1097/SP9.0000000000000051 |
| PMID | 40860205 |